T he long-term vascular response to coronary stenting can involve transformation of an otherwise benign neointima to one that resembles de novo atherosclerosis in an unstented vessel. The neointima may be infiltrated by foamy macrophages, undergo neovascularization, and develop unstable thin-cap fibroatheromas (TCFA) that contribute to neointimal disruption and thrombus formation in situ, similar to what is observed in the presence of a vulnerable plaque. 1,2 This process is known as neoatherosclerosis and is independently associated with mean in-stent neointimal thickness (odds ratio, 2.53; 95% confidence interval, 1.96-3.27; P<0.001). When present, neoatherosclerosis leads to high rates of target lesion revascularization and stent thrombosis. 1, 2 There has been growing interest in the use of intravascular optical coherence tomography (OCT) imaging to examine neointimal tissue characteristics and detect neoatherosclerosis in bare metal stents (BMS) or drug-eluting stents (DES). Several small clinical studies using this approach found that early (<6 months) after BMS implantation, the neointima was thin and homogeneous; however, after 5 years, the neointima contained lipid pools and microvessels with areas of neointimal disruption consistent with neoatherosclerosis. 3 Similar neoatherosclerotic changes have been observed in DES neointima, although the overall lipid content is reportedly higher than what was seen in BMS. 4 In one study of 50 patients with DES in-stent restenosis, OCT revealed that 52% had ≥1 in-stent neointimal TCFA and 58% had ≥1 area of in-stent neointimal disruption, suggesting that neoatherosclerosis was highly prevalent in restenosis. 5 DES neoatherosclerosis exhibits spatial heterogeneity with a predilection for the proximal and distal segments of the stent and occurs more frequently when there is an adjacent lipid-rich plaque. 6 OCT studies also indicate that neoatherosclerosis occurs earlier in DES than BMS. Although neoatherosclerosis was observed in BMS after 5 years, it was detected in DES after a median of only 32.2 months. 5 While the aforementioned studies enrolled relatively few patients, their collective findings add to an accumulating body of evidence that identifies neoatherosclerosis as a significant contributor to late stent failure. 5 The OCT findings from clinical studies are supported by detailed histopathologic examinations of in-stent neoatherosclerosis. Early pathological studies of BMS implanted for 2 to 7 years revealed chronic inflammation, neointimal microvessels, and extracellular matrix collagen deposition and matrix metalloproteinase activity. 7 A contemporary autopsy study that analyzed 197 BMS and 209 DES found similar evidence of neointimal remodeling and confirmed that neoatherosclerosis occurred earlier in DES compared with BMS (70-120 versus 900 days). Although TCFAs and plaque rupture were detectable earlier in DES than BMS (2 versus 5 years), neointimal TCFA were found more frequently in BMS (7.4%) than in DES (3.1%). 8 In this series, the incidence of neoatherosclerosis was higher in DES than BMS (31% versus 16%), despite the fact that at the time the analyses were performed, BMS had been implanted for ≈2160 days compared with only 420 days for DES. These findings are not unique to first-generation DES, and a similar histopathologic profile has been reported for second-generation DES. 8, 9 Clinical characteristics associated with in-stent neoatherosclerosis included advanced age, DES, stent implantation >4 years, tobacco use, and chronic kidney disease. 8, 10 Another study that performed histopathologic analysis of aspirated thrombectomy material from 42 patients with BMS implanted >1 year identified fragments of atherosclerotic plaques that included TCFAs, foamy macrophages, and cholesterol crystals in the aspirates. 11 Although it is not known whether or not the thrombus was retrieved from within the stent or an adjacent area, these findings add strength to the argument that in-stent neoatherosclerosis behaves the same as unstable atherosclerotic plaques. 12 Understanding the cellular mechanisms involved in neoatherosclerosis has led to a focus on the endothelium. A functional endothelium is key to preventing neoatherosclerosis, and this point was ably demonstrated by an experiment performed in normocholesterolemic rabbits implanted with a 32 P β-emitting stent. At 6 and 12 months, there was evidence of neoatherosclerosis with neointimal infiltration of inflammatory cells, foam cells, and calcification that occurred in the setting of poor reendothelialization. Because this model does not develop atherosclerosis in the absence of a high cholesterol diet, the in-stent lesions were determined to be neoatherosclerosis that was attributable to the lack of a functional endothelium. 13 This is not surprising as early studies in the era of balloon angioplasty demonstrated that the regenerated endothelial cells are structurally and functionally abnormal. These cells were irregularly sized, did not align in the direction of blood flow, and were functionally impaired with abnormal endothelium-dependent vascular reactivity. 14 Interv. 2014;7:635-637.) 
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